---
title: "Aprea Therapeutics targets Q4 2026 clinical data readout for APR-1051 Phase 1 ACESOT-1051 trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294362918.md"
description: "Aprea Therapeutics plans to accelerate enrollment in the Phase 1 ACESOT-1051 trial for its WEE1 inhibitor APR-1051, targeting a clinical data readout in Q4 2026. Early results show favorable tolerability. The development focus is shifting to uterine serous carcinoma and platinum-resistant ovarian cancer, with expansion to at least 50 patients. New combination arms are planned for HPV-positive head and neck and colorectal cancers using previously cleared dose levels."
datetime: "2026-07-30T12:10:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294362918.md)
  - [en](https://longbridge.com/en/news/294362918.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294362918.md)
generator: "portal-rs"
---

# Aprea Therapeutics targets Q4 2026 clinical data readout for APR-1051 Phase 1 ACESOT-1051 trial

-   Aprea outlined plans to accelerate enrollment in its Phase 1 ACESOT-1051 dose-escalation trial of WEE1 inhibitor APR-1051. \* Early single-agent activity was observed with a favorable tolerability profile, without reporting detailed efficacy or safety metrics. \* Next clinical results are scheduled for presentation at a medical meeting in Q4 2026. \* Development focus shifts toward uterine serous carcinoma, cyclin E-overexpressing platinum-resistant ovarian cancer, supported by an expansion to at least 50 patients. \* New combination arms are planned in HPV-positive head and neck cancer, colorectal cancer, using dose levels that have already cleared safety review. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300800PRIMZONEFULLFEED9800612) on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [APRE.US](https://longbridge.com/en/quote/APRE.US.md)

## Related News & Research

- [Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs | APRE Stock News](https://longbridge.com/en/news/297324671.md)
- [Aprea Therapeutics advances APR-1051 oncology pipeline progress](https://longbridge.com/en/news/295669266.md)
- [BlossomHill Therapeutics to present updated Phase 1/2 SOLARA trial data on BH-30643 in EGFR-mutant NSCLC at WCLC 2026](https://longbridge.com/en/news/297641175.md)
- [HCW Biologics wins USPTO patent allowance for HCW9302 use in alopecia areata treatment](https://longbridge.com/en/news/297790650.md)
- [Top Omeros Executive Makes Eye-Catching Move With Insider Stock Sale](https://longbridge.com/en/news/297721007.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**